RXi Pharmaceuticals Announces Upcoming Presentations

  RXi Pharmaceuticals Announces Upcoming Presentations

AsiaTIDES 25th Annual ROTH Conference

Business Wire

WESTBOROUGH, Mass. -- February 19, 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused
on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using RNA-targeted technologies, today announced
upcoming presentations at AsiaTIDES and at the ROTH 25th Annual Conference.

AsiaTIDES

On Tuesday, February 26, 2013 at 9:40 am JST, Karen G. Bulock, Ph.D., Vice
President of Research for RXi Pharmaceuticals will be participating in a
Tutorial Session on approaches to Successful Delivery of Oligonucleotides in
vivo, where she will discuss “Local Delivery: Lessons Learned from
'Self-Delivering' RNAi Compounds”. Dr. Bulock’s presentation will be available
on the Company's website.

On February 27, 2013 at 1:40 pm JST, RXi’s Chief Development Officer, Pamela
A. Pavco, Ph.D., will be presenting an update on RXI-109, an RNAi Compound in
Clinical Development to Reduce Dermal Scarring. RXI-109 is the first member of
a novel class of RNAi compounds, termed 'self-delivering' or sd-rxRNA, to
enter into clinical development. RXI-109 targets connective tissue growth
factor (CTGF), a key regulator of fibrosis and scar formation, and is
initially being developed to reduce or inhibit dermal scarring. Dr. Pavco’s
presentation will be available on the Company's website. This conference is
being held February 26-28, 2013 at the Sheraton Miyako Hotel, Tokyo, Japan.
For more information visit: http://www.ibclifesciences.com/AsiaTIDES

ROTH 25^th Annual Conference

The Company’s President and Chief Executive Officer, Dr. Geert Cauwenbergh,
will present at the ROTH 25^th Annual Conference on Tuesday, March 19, 2013 at
1:30 pm PT. Dr. Cauwenbergh will discuss the development of RXI-109, a
self-delivering RNAi compound designed to reduce dermal scarring, as well as
business development opportunities with RXi’s sd-rxRNA® technology platform. A
live webcast of the presentation will be available on the “Investors” section
of the Company's website, www.rxipharma.com. A replay of the presentation will
be available for 90 days. This conference is being held March 17-20, 2013at
the Ritz-Carlton Laguna Niguel in Dana Point, CA. For more information visit:
http://www.roth.com.

To schedule a meeting with RXi Pharmaceuticals at this conference, please
submit your request to oneononerequests@roth.com. The deadline is March 1,
2013 for requests.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self-delivering RNAi platform. Therapeutics that use RNA
interference, or “RNAi,” have great promise because of their ability to
down-regulate the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi’s first RNAi product candidate, RXI-109, which targets CTGF, entered into
human clinical development in June 2012. For more information, please visit
www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation’s products and
technologies. Forward-looking statements about expectations and development
plans of RXi’s products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

Contact:

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com